Dexamethasone implants in retinal vein occlusion: 12-month clinical effectiveness using repeat injections as-needed

Abstract

The intravitreal dexamethasone implant does not last the 6 months implied by the retreatment protocol in the GENEVA trial, and improved results can be achieved with an as-needed retreatment protocol, particularly in CRVO. However, visual outcomes remain similar to those previously seen with triamcinolone in the SCORE study and neovascular complications remain a feature of CRVO.

Early Effects of Dexamethasone Implant on Macular Morphology and Visual Function in Patients with Macular Edema Secondary to Retinal Vein Occlusion

“…Unfortunately, no conclusions can be drawn from this study on the effects of steroidal therapy on CRT sooner than 3 months after treatment initiation. Other studies investigated the efficacy of Ozurdex with a monthly OCT evaluation and showed that notable morphological improvements can be seen as soon as 1 month after treatment [11,12,13]. …”

Twelve-month Outcomes of Dexamethasone Implant Treatment in Macular Edema Secondary to Retinal Vein Occlusion in Real Life

“…Mean number of injections was reported to be 2.8 and 2.0 in ischemic CRVO and BRVO groups, respectively. Joshi et al reported 12-month outcomes of IDI treatment in as needed treatment regimen (16). Retrospectively, 51 eyes of 49 patients were included.…”

Dexamethasone Intravitreal Implant in Patients with Macular Edema Due to Central Retinal Vein Occlusion: Six Months Results

“…[8][9][10][11][12][13][14][15][16] Lipofilik bir kortikosteroid olan triamsinolonun aksine suda çö-zünen deksametazonun intravitreal kullanımının, göz içi basıncını daha az artırdığı ve katarakt oluşumunu daha az uyardığı bildirilmiştir. [17][18][19][20][21] Deksametazon, suda çözünen, etkili ve intravitreal boşluğa verilebilen bir steroiddir. İntravit-real deksametazon implantı (İVD) olan Ozurdex (OZURDEX, Allergan, Inc., Irvine, California), yavaş salınımlı ve laktik asit ve glikolik asit içeren biyodçözünür bir kopolimerdir.…”

“…Farmakokinetik ve farmakodinamik çalışmalar implantın etkinliğini altı ay olarak belirtse de, implantın klinik etkinliği ikinci aydan itibaren düşmeye başlamaktadır. [20][21][22][23][24] Bu çalışmada, SRVT'ye bağlı MÖ tedavisinde uyguladığımız tek doz 0,7 mg deksametazon implantın klinik etkinliği ve bu etkinliğin süresinin öl-çülmesi amaçlanmıştır.…”